David V. Jobes
Fondateur chez Mid-Atlantic BioTherapeutics, Inc.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Jean-Pierre Gagnon | M | - |
Mid-Atlantic BioTherapeutics, Inc.
 Mid-Atlantic BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mid-Atlantic BioTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. The company was founded by David Horn, David Jobes, and Jean-Pierre Gagnon in 2011 and is headquartered in Doylestown, PA. | 13 ans |
| David Horn | M | - |
Mid-Atlantic BioTherapeutics, Inc.
Mid-Atlantic BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mid-Atlantic BioTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. The company was founded by David Horn, David Jobes, and Jean-Pierre Gagnon in 2011 and is headquartered in Doylestown, PA. | 13 ans |
| Michael J. Goldblatt | M | - |
Mid-Atlantic BioTherapeutics, Inc.
Mid-Atlantic BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mid-Atlantic BioTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. The company was founded by David Horn, David Jobes, and Jean-Pierre Gagnon in 2011 and is headquartered in Doylestown, PA. | - |
| Julian Chick | M | - |
Mid-Atlantic BioTherapeutics, Inc.
Mid-Atlantic BioTherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mid-Atlantic BioTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. The company was founded by David Horn, David Jobes, and Jean-Pierre Gagnon in 2011 and is headquartered in Doylestown, PA. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Elena Viboch | F | - |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | 1 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 5 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- David V. Jobes
- Réseau Personnel
